Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

Gynecologic Oncology

Volumn 129, Issue 1, 2013, Pages 69-73

  Worley Jr , Michael J ^a   Guseh, Stephanie H ^a   Rauh Hain, J Alejandro ^b   Williams, Kristina A ^c   Muto, Michael G ^a   Feltmate, Colleen M ^a   Berkowitz, Ross S ^a   Horowitz, Neil S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Elderly; Neoadjuvant chemotherapy; Ovarian cancer; Readmission

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HOSPITAL READMISSION; HUMAN; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; PERITONEUM CANCER; PEROPERATIVE COMPLICATION; PLEURA EFFUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; UTERUS CARCINOMA;

AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; LENGTH OF STAY; NEOADJUVANT THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATIENT READMISSION; PERITONEAL NEOPLASMS; RISK FACTORS;

EID: 84875447641     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.01.012     Document Type: Article

References (30)

1. American Cancer Society Cancer Facts and Figures 2012 2012 American Cancer Society Atlanta, GA
2. L.A. Gloeckler Ovarian cancer: survival and treatment differences by age Cancer 71 1993 524 529
3. U.A. Matulonis, K.J. Krag, C.N. Krasner, T. Atkinson, N.S. Horowitz, and H. Lee Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors Gynecol Oncol 112 2009 394 399
4. D. Uyar, H.E. Frasure, M. Markman, and V.E. von Gruenigen Treatment patterns by decade of life in elderly women (> or = 70 years of age) with ovarian cancer Gynecol Oncol 98 3 2005 403 408 [Sep]
5. L.A. Ries Ovarian cancer. Survival and treatment differences by age Cancer 71 1993 524 529
6. R.D. Hightower, H.N. Nguyen, H.E. Averette, W. Hoskins, T. Harrison, and A. Steren National survey of ovarian carcinoma. IV: patterns of care and related survival for older patients Cancer 73 1994 377 383
7. J. Wright, T. Doan, R. McBride, J. Jacobson, and D. Hershman Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival Br J Cancer 98 7 2008 1197 1203 [Apr 8]
8. D. Hershman, J.S. Jacobson, R. McBride, N. Mitra, V. Sundararajan, and V.R. Grann Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer Gynecol Oncol 94 2004 540 549
9. L.F. Hutchins, J.M. Unger, J.J. Crowley, C.A. Coltman Jr., and K.S. Albain Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 27 1999 2061 2067 [Dec 30]
10. D.H. Moore, J.T. Kauderer, J. Bell, J.P. Curtin, and L. Van Le An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study Gynecol Oncol 94 2 2004 368 374 [Aug]
11. P.E. Schwartz What is the role of neoadjuvant chemotherapy in the management of ovarian cancer? Oncology (Williston Park) 22 2008 1118 1125 [discussion 1130, 1132, 1134]
12. P.E. Schwartz Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer Curr Oncol Rep 11 2009 457 465
13. I. Vergote, C.G. Tropé, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson Neoadjuvant chemotherapy or primary surgery in Stage IIIC or IV ovarian cancer N Engl J Med 363 2010 943 953
14. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 2009 2315 2320
15. M.A. Glasgow, H. Yu, T.J. Rutherford, M. Azodi, D.A. Silasi, and A.D. Santin Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV) J Surg Oncol May 30 2012
16. G.D. Aletti, S.C. Dowdy, K.C. Podratz, and W.A. Cliby Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer Am J Obstet Gynecol 197 6 Dec 2007 676.e1 676.e7
17. C. Langstraat, G.D. Aletti, and W.A. Cliby Morbidity, mortality and overall survival in elderly women undergoing primary surgical debulking for ovarian cancer: a delicate balance requiring individualization Gynecol Oncol 123 2 Nov 2011 187 191
18. J.D. Wright, T.J. Herzog, and M.A. Powell Morbidity of cytoreductive surgery in the elderly Am J Obstet Gynecol 190 5 May 2004 1398 1400
19. S. Sharma, D. Driscoll, K. Odunsi, A. Venkatadri, and S. Lele Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients Am J Obstet Gynecol 193 6 Dec 2005 2077 2082
20. K.N. Moore, M.S. Reid, D.N. Fong, T.K. Myers, L.M. Landrum, and K.M. Moxley Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol 110 2 Aug 2008 133 139
21. S. Kang, and B.H. Nam Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies Ann Surg Oncol 16 8 Aug 2009 2315 2320
22. I. Vergote, C.G. Tropé, F. Amant, G.B. Kristensen, T. Ehlen, and N. Johnson European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer N Engl J Med 363 10 Sep 2 2010 943 953
23. International Federation of Health Plans Comparative price report Retrieved from http://www.ifhp.com/news97.html 2011
24. D. Foster, and G. Harkness Healthcare reform: pending changes to reimbursement for 30-day readmissions 2010 Thomson Reuters Ann Arbor (MI)
25. S.F. Jencks, M.V. Williams, and E.A. Coleman Rehospitalizations among patients in the Medicare fee-for-service program N Engl J Med 360 2009 1418 1428
26. B.S. Brooke, R.R. De Martino, M. Girotti, J.B. Dimick, and P.P. Goodney Developing strategies for predicting and preventing readmissions in vascular surgery J Vasc Surg 56 2 Aug 2012 556 562
27. M.C. Renaud, M. Plante, J. Grégoire, and M. Roy Ovarian cancer in the elderly patient: are we doing enough? J Obstet Gynaecol Can 32 11 Nov 2010 1049 1055
28. D.P. O'Brien, A. Senagore, J. Merlino, K. Brady, and C. Delaney Predictors and outcome of readmission after laparoscopic intestinal surgery World J Surg 31 12 2007 2430 2435 [Dec]
29. Y. Kariv, W. Wang, A.J. Senagore, J.P. Hammel, V.W. Fazio, and C.P. Delaney Multivariable analysis of factors associated with hospital readmission after intestinal surgery Am J Surg 191 2006 364 371
30. J.M. Fauci, K.E. Schneider, P.J. Frederick, G. Wilding, J. Consiglio, and A.L. Sutton Assessment of risk factors for 30-day hospital readmission after surgical cytoreduction in epithelial ovarian carcinoma Int J Gynecol Cancer 21 5 Jul 2011 806 810